Anti-BTLA / CD272 Reference Antibody (icatolimab)
- Product Code: 139831
| Molecular Weight: | Molecular Formula: | ||
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Used in the treatment of various cancers, particularly in clinical development for solid tumors and hematologic malignancies. It functions as an immune checkpoint modulator by blocking the BTLA (B- and T-lymphocyte attenuator) pathway, thereby enhancing T-cell activation and anti-tumor immune responses. Currently being evaluated in combination with other immunotherapies to improve efficacy in patients with advanced cancers. Also serves as a reference standard in preclinical and clinical studies for evaluating BTLA-targeting therapeutics.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 10-20 days | ฿4,980.00 |
+
-
|
Anti-BTLA / CD272 Reference Antibody (icatolimab)
Used in the treatment of various cancers, particularly in clinical development for solid tumors and hematologic malignancies. It functions as an immune checkpoint modulator by blocking the BTLA (B- and T-lymphocyte attenuator) pathway, thereby enhancing T-cell activation and anti-tumor immune responses. Currently being evaluated in combination with other immunotherapies to improve efficacy in patients with advanced cancers. Also serves as a reference standard in preclinical and clinical studies for evaluating BTLA-targeting therapeutics.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :